Home
    Scientific Program
    Faculty
    Registration
    Accommodation
     Welcome Note
     Conference Chairmen
     Faculty
     Timetable
     Scientific Program
     Poster Presentations
         Poster Presentation Guidelines
     When you arrive in Berlin...
     Abstract Submission
     Registration
     Accommodation
         Leonardo Royal Hotel Berlin
     Sponsorship & Exhibition
     Sponsors
     CME
     General Information
         Tips & Hints
     Italian Agent
     Invitation Letter
     Partners
     About Berlin
     Conference Secretariat
1st International Conference on
Controversies in Vaccination in Adults (CoVAC)
January 27-30, 2011, Berlin, Germany
 
  Scientific Program Print
Friday, January 28, 2011 Hall A
 
08:30-08:45 Opening Ceremony by the Conference Chairmen
H. Lode, Germany; E. Rubinstein, Canada
 
Opening Address
G. Höffken, Germany, President of the Paul-Ehrlich-Society
 
 
Session 1  
08:45-10:15
Pneumococcal Vaccine (I)
CME session supported by an unrestricted educational grant by Pfizer
Capsule: Pneumococcal vaccine has caused a substantial decrease in invasive disease.
 
Chairperson K. Klugman, USA
08:45-08:55 Overview of pneumococcal vaccines beneficial effects
 
 
Debate: Is hyporesponsiveness with polysaccharide vaccines a problem?
  
08:55-09:10    Pro: D. Goldblatt, UK
09:10-09:25    Con: R.R. Reinert, Italy
 
 
09:25-09:35 Discussion
 
  
Debate: Are the effects of polysaccharide vaccines long lasting?
Moderator: J. Garau, Spain
  
09:35-09:50    Pro: A. Ortqvist, Sweden
09:50-10:05    Con: D. Fedson, France
 
  
10:05-10:15
 
Discussion
   
  
10:15-10:45 Coffee Break
  
 
Session 2  
10:45-12:30 Pneumococcal Vaccine (II)
Capsule: The role of pneumococcal vaccinations continues; more answers or more confusion?
 
Moderator G. Höffken, Germany
 
 
Debate: Did the last Influenza (H1N1) epidemic provide answers to the dilemmas or add to the confusion on the impact of pneumococcal vaccination?
  
10:45-11:00    Pro: K. Klugman, USA
11:00-11:15    Con: T. Welte, Germany
   
  
11:15-11:30 Discussion
  
11:30-12:30 Round Table Discussion
Questions

-

Is there a compensatory increase in non-vaccine pneumococcal type carriage? Infection?

-

Effect on other pathogens?

-

Which vaccine to use in adults?

-

What is the optimal timing of pneumococcal vaccinations?
  
Discussants
G. Regev-Yochay, Israel
W.R. Neumann, USA
  
 

12:30-13:30

Lunch Break
 
  
 
Session 3
13:30-15:00     H1N1 pandemic: Much Ado About Nothing?
Chairperson:
M. Pfleiderer, Germany
 
13:30-13:35
Introduction
 
13:35-14:00 Influenza pandemics: Do we still need to prepare?
T. Schaberg, Germany

 
14:00-14:25
(Pre-)pandemic preparedness & coordination
in Germany: Status Quo & future perspectives. 
H. Uphoff, Germany
  
14:25-14:50
Challenges for implementation of the pandemic vaccination programme: the Swedish experience
A. Örtqvist, Sweden
 
14:50-15:00 Summary/Discussion
M. Pfleiderer, Germany
 
  
  
15:00-15:15 Coffee Break
 
 
Session 4  
15:15-16:30 Seasonal Flu Vaccine
Capsule: Immunization of seasonal vaccine reduces morbidity and mortality
 
Chairperson T. Welte, Germany
 
  
Debate: Is the vaccine efficacious in changing overall morbidity and mortality?
  
15:15-15:30    Pro: M. Pletz, Germany
15:30-15:45    Con: E. Rubinstein, Canada
  
  
15:45-16:00 Discussion
  
16:00-16:30 Round Table discussion
Questions

-

Is there solid evidence for this statement?

-

Who is paying the price?

-

Who is benefitting?

-

Nasal vs. conventional vaccines

-

Live vs. killed vaccines
  
Discussants
R. Arnon, Israel
W.P. Glezen, USA
E. Hak, The Netherlands
  
  
Friday, January 28, 2011 Hall B
 
Session 4.1
15:15-16:30
Free Communications I
 
Chairperson
G. Höffken, Germany
 
15:15-15:37
Future of Vaccination
 
15:15-15:23
Challenges in Designing Vaccine Clinical Trials in Elderly Populations
J. Kou, USA
15:23-15:26
Discussion
 
15:26-15:34
"Do as I say, not as I do", nurses and immunizations
O. Baron-Epel, Israel
15:34-15:37
Discussion
 
15:37-15:59
Seasonal Flu Vaccine
 
15:37-15:45
The influenza vaccination of healthcare workers: Is a new approach needed? Yes!
S. Wicker, Germany
15:45-15:48
Discussion
 
15:48-15:56
Seasonal influenza vaccine effectiveness in an Italian adult population: the Moli-flu study
S. Costanzo, Italy
15:56-15:59
Discussion
 
15:59-16:21
Meningococcal Vaccine
 
15:59-16:07
Challenges in evaluation of protective vaccine efficacy based on immunogenicity surrogate endpoints
B. Krasnicka, USA
16:07-16:10
Discussion
 
16:10-16:18
Vaccination of late complement component-deficient (LCCD) adults: new possibilities, new questions
A. Platonov, Russia
16:18-16:21
Discussion
 
16:21-16:30
Summary
 
   
Friday, January 28, 2011 Hall A
   
Session 5  
16:30-17:45 Pseudomonas aeruginosa
Capsule: Resistance of Pseudomonas aeruginosa – an international therapeutic challenge
 
Chairperson N. Höiby, Denmark
16:30-16:40 Clinical importance of Pseudomonas aeruginosa infections
  
  
Debate: Will we ever have an effective Pseudomonas aeruginosa vaccine?
  
16:40-16:55    Pro: G. Döring, Germany
16:55-17:10    Con: G. Pier, USA
 
 
17:10-17:25 Discussion
 
17:25:17:45 Round Table Discussion
Questions

-

Who are the right patients for this vaccine?

-

How long will the protection last?

-

Who will pay?
  
Discussant
K. Weiss, Canada
 
  
Friday, January 28, 2011 Hall B
   
Session 5.1
16:30-17:35
Free Communications II
 
Chairperson
G. Höffken, Germany
 
16:30-17:03
H1N1 Swine Flu Vaccine
 
16:30-16:38
Herd immunity after A/H1N1sw pandemic: Implications for the 2010/11 seasonal influenza
J. Cramer, Germany
16:38-16:41
Discussion
 
16:41-16:49
K newspapers’ representations of the swine flu pandemic: a health scare over-hyped by the news media?
S. Hilton, UK
16:49-16:52
Discussion
 
16:52-17:00
H1N1 2009 influenza vaccination campaign in Israel: Preparedness and Response
I. Grotto, Israel
17:00-17:03
Discussion
 
17:03-17:14
HPV Vaccine
 
17:03-17:11
Less clearance of HPV 16 after vaccination of HPV 16 positive women with prophylactic HPV vaccines
C. Depuydt, Belguim
17:11-17:14
Discussion
 
17:14-17:25
Staphylococcal Vaccine
 
17:14-17:22
Preclinical Development of a Bio-Conjugate Vaccine to Prevent Staphylococcus aureus Infection
J. Lee, USA
17:22-17:25
Discussion
 
17:25-17:35
Summary
 
  
Saturday, January 29, 2011 Hall A
 
Session 6
08:30-09:45 Staphylococcal Vaccine
Capsule: Current situation of staphylococcal vaccine
 
Chairperson J. Lee, USA
08:30-08:40 Overview
 
 
Debate: Is there a future for an effective staphylococcal vaccine?
  
08:40-08:55    Pro: R. Proctor, USA
08:55-09:10    Con: G. Peters, Germany
 
  
09:10-09:25 Discussion
 
09:25-09:45 Round Table Discussion
Questions

-

Can an effective Staphylococcal vaccine finish the MRSA epidemic?

-

Which population to vaccinate?

-

What will happen to the normal body flora?
  
Discussant
S. Foster, UK
 
 
09:45-10:15

Coffee Break

 
 
Session 7
10:15-11:45 VZV Vaccine
Capsule: VZV vaccine decreases PHN and burden of disease in the elderly
 
Chairperson A. Gershon, USA
10:15-10:25 Overview
 
  
Debate: Is there a need for HZV vaccine in the elderly – that is only 50-60% efficacious?
  
10:25-10:40    Pro: P. Wutzler, Germany
10:40-10:55    Con: E. Rubinstein, Canada
  
 
10:55-11:10 Discussion
 
11:10-11:45 Round Table Discussion
Questions

-

What questions are still open following the Herpes Zoster vaccine trial in the elderly?

-

How long does immunity last? Is a booster necessary?

-

Special populations – will they benefit?
  
Discussant
H. Lode, Germany
  
 
Saturday, January 29, 2011 Hall B
 
Session 12
10:15-11:45 Tuberculosis Vaccine
Capsule: MTB infections are a world-wide unresolved problem
 
Chairperson C. Lange, Germany
10:15-10:25 Overview: Tb burden worldwide
 
  
Debate: Will an effective and affordable Tb vaccine be available in the near future?
  
10:25-10:40    Pro: S. Kaufmann, Germany
10:40-10:55    Con: H. Rieder, Switzerland
  
  
11:55-11:15 Discussion
  
11:15-11:45 Round Table Discussion
Questions

-

Is an effective anti-Tb vaccine the solution for the global Tb-epidemic?

-

Who will pay in poor countries?

-

Free access in Africa?
 
Discussants
R. Loddenkemper, Germany
H. Bercovier, Israel
 
 
Saturday, January 29, 2011 Hall A
 
Session 8  
11:45-13:00 Meningococcal Vaccine
Capsule: Meningococcal vaccine has changed the epidemiology of the disease, why are we still seeing cases?
 
Chairperson R. Rappuoli, Italy
11:45-11:55 Overview: Tb burden worldwide
 
  
Debate: Has the vaccine changed the global epidemiology of the meningococcal disease?
  
11:55-12:10    Pro: A. Shibl , Saudi Arabia
12:10-12:25    Con: J. Garau, Spain
  
 
12:25-12:35 Discussion
  
12:35-13:00 Round Table Discussion
Questions

-

Is the bug smarter than the vaccine?

-

The future?

-

The problem in the developing world Group B
 
Discussant
K. Klugman, USA
 
 
Saturday, January 29, 2011 Hall B
 
Session 13
11:45-13:00 HPV Vaccine
Capsule: Cervical Cancer and Human Papilloma Virus (HPV): Does vaccination mark the end of cervical cancer?
 
Chairperson
11:45-12:00
F. X. Bosch, Spain
Overview of HPV: changes in global epidemiology
 
12:00-12:15
Shall we extend the indications of HPV vaccination?
E. Joura, Austria
  
12:15-13:00 Discussion
 
Questions

-

What is the difference between quadrivalent or bivalent HPV vaccine?

-

For how long does immunization provide immunity?

-

Does current knowledge imply immunization against cancer, or merely precancerous stages?

-

Do the vaccines protect against other HPV subtypes as well as HPV 16 and 18? Is there cross reactivity?
  
Discussant
H. Ikenberg, Germany
 
  

13:00-14:00

Lunch Break
 
 
Saturday, January 29, 2011 Hall A
 
Session 9 Plenary Session
14:00-15:30
The Influenza Paradox
CME Session supported by an unrestricted educational grant by Abbott
Capsule: there is a huge gap between most current national guidelines and their implementation. Are physicians not convinced of the evidence and comply with the guidelines or is national health infrastructure insufficient to support full implementation? Many at risk patients fail to receive advice about flu vaccination: whose responsibility is it?
  
Chairperson
D. Low, Canada
Introduction
   
14:00-14:20
Increasing protection from influenza vaccination: universal vaccination and other alternatives
D. Fedson, France
 
14:20-14:40
How disabling can influenza be. Can vaccination prevent this and to what extent?
J. McElhaney, Canada
  
14:40-15:00
Should national policy guidelines be implemented regardless of physician own views?
A. Tegnell, Sweden
 
15:00-15:30 Discussion
   
  Questions

 -

Does influenza vaccination provide protection during pre-influenza seasons and, if so, how should we interpret observational studies showing vaccination is protective during influenza seasons?

 -

What can be done to improve public and expert acceptance of adjuvanted influenza vaccines?

 -

For influenza vaccination policy decisions, how much prevention is enough?
 
 
Saturday, January 29, 2011 Hall A
 
Session 10
16:00-17:15 H1N1 Swine Flu Vaccine
Capsule: The H1N1 vaccine has helped by blocking the epidemic in certain countries
 
Chairperson P. Wutzler, Germany
16:00-16:10 Overview of the H1N1 vaccine beneficial effects
 
  
Debate Did the H1N1 vaccine change the epidemiology of the recent H1N1 pandemic?
  
16:10-16:25    Pro: A. Osterhaus, The Netherlands
16:25-16:35    Con: R. Rappuoli, Italy
  
 
16:35-16:40 Discussion
  
16:40-17:15 Round Table Discussion
Questions

-

Adjuvanted vs. unadjuvanted vaccines

-

Which populations to vaccinate?

-

Interaction between seasonal vaccines and H1N1 In special populations

-

Vaccine A E's
  
Discussants
E.N. Janoff, USA
H.J. Schmitt, Germany
A. Ortqvist, Sweden
 
 
Saturday, January 29, 2011 Hall B
 
Session 14  
16:00-17:15 Anti-Smoking Vaccine
Capsule: Cigarette smoking – the leading global killer
  
Chairperson H. Lode, Germany
16:00-16:10 Overview
  
  
Debate: Will a vaccine be successful?
  
16:10-16:25    Pro: J. Cornuz, Switzerland
16:25-16:40    Con: T. Schaberg, Germany
   
  
16:40-16:55 Discussion
  
16:55-17:15 Round Table Discussion
Questions

-

Are there better means

-

Political aspects

-

Which population should be vaccinated?

-

Should the vaccination be mandatory?
 
Discussant
G. Höffken, Germany
  
 
Saturday, January 29, 2011 Hall A
 
Session 11
17:15-18:30 Clostridium difficile Vaccine
Capsule: Clostridium difficile is a preventable infection, is the vaccine the right solution?
  
Chairperson H. Bercovier, Israel
17:15-17:20 Overview
  
 
Debate: Will it work? For whom?
  
17:20-17:35    Pro: D. Gerding, USA
17:35-17:50    Con: A. Rodloff, Germany
  
 
17:50-18:00 Discussion
 
18:00-18:30 Round Table Discussion
Questions

-

New vaccines for Clostridium difficile

-

What effective hygienic measurements are available?

-

Which patient should be vaccinated?

-

Who will pay?
 
Discussant
P. Gastmeier, Germany
 
 
Saturday, January 29, 2011 Hall B
  
Session 15  
17:15-18:30 Anthrax and Smallpox Vaccines
 
Chairperson A. Ortqvist, Sweden
17:15-17:25 Overview
 
17:25-17:40 Next Generation Anthrax Vaccines
A. Friedlander, USA
  
17:40-18:30 Discussion
  
Question

-

Could vaccines be effective in bioterrorismus?
  
Discussant
J. Grabenstein, USA
 
  
Sunday, January 30, 2011 Hall A
  
Session 16  
09:00-10:00 H5N1 Bird Flu Vaccine
Capsule: Does Bird Flu constitute an eminent global threat?
  
H.W. Doerr, Germany
Introduction
 
 
Debate: Does Bird Flu constitute an eminent global threat?

09:00-09:15     Pro: A. Osterhaus, The Netherlands
09:15-09:30     Con: D.Fedson, France

 
  
09:30-10:00 Discussion
  
 
Session 17
10:00-11:30 Future of Vaccination
Capsule: Experts opinion on the future of vaccination
  

Chairpersons

H. Lode, Germany; E. Rubinstein, Canada
  
10:00-10:30 Basic sciences
R. Arnon, Israel
 
10:30-11:00 Clinical aspects: VZV Vaccines
A. Gershon, USA
  
11:00-11:30 Ethical aspects
B. Velan, Israel
  
  
11:30-12:00 Summary
  
Chairpersons H. Lode, Germany; E. Rubinstein, Canada
  

Home   
Copyright © 2007 comtecmed.com. All rights reserved.   The website was last updated on 07/13/2011 Created by     WebStudio.co.il